UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/19.03.25 | Real-time Bid/Ask 09:43:16 05/07/2024 BST | ||
| 4.58 EUR / 4.79 EUR | +2.52% |
|
| Current month | +1.33% | ||
| 1 month | -1.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 4.48 | -1.97% |
| 04/07/24 | 4.57 | -5.77% |
| 03/07/24 | 4.85 | +5.90% |
| 02/07/24 | 4.58 | -2.76% |
| 01/07/24 | 4.71 | +4.43% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 08:08 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD4420 |
| ISIN | DE000HD44202 |
| Date issued | 25/03/2024 |
| Strike | 500 $ |
| Maturity | 19/03/2025 (258 Days) |
| Parity | 10 : 1 |
| Emission price | 8.73 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.23 € |
|---|---|
| Lowest since issue | 4.09 € |
| Spread | 0.21 € |
| Spread % | 4.38% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
